{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:48:09Z","timestamp":1793882889018,"version":"4.7.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>From this retrospective study, we aimed to (1) describe the prevalence and characteristics of non-criteria features in primary antiphospholipid syndrome (p-APS) and (2) determine their prognostic value.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective French multicenter cohort study included all patients diagnosed with p-APS (Sydney criteria) between January 2012 and January 2019. We used Kaplan-Meier and adjusted Cox proportional hazards models to compare the incidence of relapse in p-APS with and without non-criteria manifestations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and seventy-nine patients with p-APS were included during the study time, with a median age of 52.50 years [39.0; 65.25] and mainly women (<jats:italic>n<\/jats:italic>= 112; 62.6%). Among them, forty-three patients (24.0%) presented at least one non-criteria manifestation during the follow-up: autoimmune cytopenias (<jats:italic>n<\/jats:italic>= 17; 39.5%), Libman Sachs endocarditis (<jats:italic>n<\/jats:italic>= 5; 11.6%), APS nephropathy (<jats:italic>n<\/jats:italic>= 4; 9.3%), livedo reticularis (<jats:italic>n<\/jats:italic>= 8; 18.6%), and neurological manifestations (<jats:italic>n<\/jats:italic>= 12; 27.9%). In comparison to p-APS without any non-criteria manifestations (<jats:italic>n<\/jats:italic>= 136), p-APS with non-criteria features had more arterial thrombosis (<jats:italic>n<\/jats:italic>= 24; 55.8% vs<jats:italic>n<\/jats:italic>= 48; 35.3%;<jats:italic>p<\/jats:italic>= 0.027) and more frequent pre-eclampsia (<jats:italic>n<\/jats:italic>= 6; 14.3% vs<jats:italic>n<\/jats:italic>= 4; 3.1%;<jats:italic>p<\/jats:italic>= 0.02). The prevalence of triple positivity was significantly increased in patients with non-criteria features (<jats:italic>n<\/jats:italic>= 20; 47.6% vs<jats:italic>n<\/jats:italic>= 25; 19.8%;<jats:italic>p<\/jats:italic>= 0.001). Patients with p-APS and non-criteria manifestations (<jats:italic>n<\/jats:italic>= 43) received significantly more additional therapies combined with vitamin K antagonists and\/or antiaggregants. Catastrophic APS (CAPS) tended to be more frequent in p-APS with non-criteria features (<jats:italic>n<\/jats:italic>= 2; 5.1% vs none;<jats:italic>p<\/jats:italic>= 0.074).<\/jats:p><jats:p>The p-APS with non-criteria manifestations had significantly increased rates of relapse (<jats:italic>n<\/jats:italic>= 20; 58.8% vs 33; 33.7%;<jats:italic>p<\/jats:italic>= 0.018) in bivariate analysis, but in survival analyses, the hazard ratio (HR) of relapse was not significantly different between the two groups (HR at 1.34 [0.67; 2.68];<jats:italic>p<\/jats:italic>= 0.40).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The presence of non-criteria features is important to consider, as they are associated with particular clinical and laboratory profiles, increased risk of relapse, and need for additional therapies. Prospective studies are necessary to better stratify the prognosis and the management of p-APS.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13075-022-02726-9","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T09:03:15Z","timestamp":1643101395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Alexis F.","family":"Gu\u00e9don","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Catano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Ricard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"de Moreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Urbanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Deriaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigorios","family":"Gerotziafas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Elalamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Audemard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Chasset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Alamowitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Sellam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Maillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Jacques","family":"Boffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Abisror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e8ne","family":"Mekinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"issue":"2","key":"2726_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295\u2013306.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2726_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.autrev.2015.01.002","volume":"14","author":"MM Abreu","year":"2015","unstructured":"Abreu MM, Danowski A, Wahl DG, Amigo M-C, Tektonidou M, Pacheco MS, et al. The relevance of \u201cnon-criteria\u201d clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401\u201314.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"2726_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nrrheum.2017.124","volume":"13","author":"S Sciascia","year":"2017","unstructured":"Sciascia S, Amigo M-C, Roccatello D, Khamashta M. Diagnosing antiphospholipid syndrome: \u201cextra-criteria\u201d manifestations and technical advances. Nat Rev Rheumatol. 2017;13(9):548\u201360.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"2726_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semarthrit.2017.12.006","volume":"48","author":"M Radin","year":"2018","unstructured":"Radin M, Ugolini-Lopes MR, Sciascia S, Andrade D. Extra-criteria manifestations of antiphospholipid syndrome: risk assessment and management. Semin Arthritis Rheum. 2018;48(1):117\u201320.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"2726_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","volume":"8","author":"V Pengo","year":"2010","unstructured":"Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost JTH. 2010;8(2):237\u201342.","journal-title":"J Thromb Haemost JTH"},{"issue":"1","key":"2726_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/art.24232","volume":"61","author":"MG Tektonidou","year":"2009","unstructured":"Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Care Res. 2009;61(1):29\u201336.","journal-title":"Arthritis Care Res"},{"issue":"12","key":"2726_CR7","doi-asserted-by":"publisher","first-page":"102689","DOI":"10.1016\/j.autrev.2020.102689","volume":"19","author":"G Pires da Rosa","year":"2020","unstructured":"Pires da Rosa G, Bettencourt P, Rodr\u00edguez-Pint\u00f3 I, Cervera R, Espinosa G. \u201cNon-criteria\u201d antiphospholipid syndrome: a nomenclature proposal. Autoimmun Rev. 2020;19(12):102689.","journal-title":"Autoimmun Rev"},{"key":"2726_CR8","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3389\/fimmu.2018.00864","volume":"9","author":"M Fredi","year":"2018","unstructured":"Fredi M, Andreoli L, Aggogeri E, Bettiga E, Lazzaroni MG, Le Guern V, et al. Risk factors for adverse maternal and fetal outcomes in women with confirmed aPL positivity: results from a multicenter study of 283 pregnancies. Front Immunol. 2018;9:864.","journal-title":"Front Immunol"},{"issue":"5","key":"2726_CR9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/1471-0528.15469","volume":"126","author":"GR de Jes\u00fas","year":"2019","unstructured":"de Jes\u00fas GR, Sciascia S, Andrade D, Barbhaiya M, Tektonidou M, Banzato A, et al. Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. BJOG Int J Obstet Gynaecol. 2019;126(5):656\u201361.","journal-title":"BJOG Int J Obstet Gynaecol"},{"issue":"6","key":"2726_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","volume":"74","author":"R Cervera","year":"2015","unstructured":"Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ram\u00f3n E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74(6):1011\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2726_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/0961203316657433","volume":"26","author":"CM Yelnik","year":"2017","unstructured":"Yelnik CM, Urbanski G, Drumez E, Sobanski V, Maillard H, Lanteri A, et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus. 2017;26(2):163\u20139.","journal-title":"Lupus."},{"key":"2726_CR12","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.3389\/fimmu.2019.01948","volume":"10","author":"M-G Lazzaroni","year":"2019","unstructured":"Lazzaroni M-G, Fredi M, Andreoli L, Chighizola CB, Del Ross T, Gerosa M, et al. Triple antiphospholipid (aPL) antibodies positivity is associated with pregnancy complications in aPL carriers: a multicenter study on 62 pregnancies. Front Immunol. 2019;10:1948.","journal-title":"Front Immunol"},{"issue":"7","key":"2726_CR13","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.autrev.2017.05.006","volume":"16","author":"A Mekinian","year":"2017","unstructured":"Mekinian A, Alijotas-Reig J, Carrat F, Costedoat-Chalumeau N, Ruffatti A, Lazzaroni MG, et al. Refractory obstetrical antiphospholipid syndrome: features, treatment and outcome in a European multicenter retrospective study. Autoimmun Rev. 2017;16(7):730\u20134.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2726_CR14","first-page":"37","volume":"45","author":"A Mekinian","year":"2017","unstructured":"Mekinian A, Kayem G, Cohen J, Carbillon L, Abisror N, Josselin-Mahr L, et al. Obstetrical APS: is there a place for additional treatment to aspirin-heparin combination? Gynecol Obstet Fertil Senol. 2017;45(1):37\u201342.","journal-title":"Gynecol Obstet Fertil Senol"},{"issue":"1","key":"2726_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0961203312465782","volume":"22","author":"J Alijotas-Reig","year":"2013","unstructured":"Alijotas-Reig J. Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus. 2013;22(1):6\u201317.","journal-title":"Lupus."},{"issue":"1","key":"2726_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.autrev.2014.08.040","volume":"14","author":"A Mekinian","year":"2015","unstructured":"Mekinian A, Costedoat-Chalumeau N, Masseau A, Tincani A, De Caroli S, Alijotas-Reig J, et al. Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? Autoimmun Rev. 2015;14(1):23\u20139.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"2726_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11926-020-00935-2","volume":"22","author":"E Xourgia","year":"2020","unstructured":"Xourgia E, Tektonidou MG. Management of non-criteria manifestations in antiphospholipid syndrome. Curr Rheumatol Rep. 2020;22(9):51.","journal-title":"Curr Rheumatol Rep"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02726-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02726-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02726-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T07:05:17Z","timestamp":1700118317000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02726-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2726"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02726-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]},"assertion":[{"value":"12 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An ethical committee was not required for this observational study according to Helsinki law and the French institutional committee. Yes, obtained from patients and coauthors","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Yes, obtained from patients and coauthors","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}